Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1196156-59-8 | MDL No. : | MFCD13189630 |
Formula : | C5H2Br2ClN | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | ZDPXTYKMHYSMQW-UHFFFAOYSA-N |
M.W : | 271.34 | Pubchem ID : | 20280769 |
Synonyms : |
|
Num. heavy atoms : | 9 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 44.65 |
TPSA : | 12.89 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.45 cm/s |
Log Po/w (iLOGP) : | 2.29 |
Log Po/w (XLOGP3) : | 3.53 |
Log Po/w (WLOGP) : | 3.26 |
Log Po/w (MLOGP) : | 2.6 |
Log Po/w (SILICOS-IT) : | 3.42 |
Consensus Log Po/w : | 3.02 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -4.24 |
Solubility : | 0.0156 mg/ml ; 0.0000576 mol/l |
Class : | Moderately soluble |
Log S (Ali) : | -3.48 |
Solubility : | 0.0888 mg/ml ; 0.000327 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.34 |
Solubility : | 0.0123 mg/ml ; 0.0000452 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.88 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With potassium phosphate; palladium diacetate; In water; N,N-dimethyl-formamide; at 130℃; for 10.0h;Inert atmosphere; | In a 250 ml three-necked flask, 2-bromo-4,6-dichloropyrimidine (0.012 mol), 4-pyridine-phenylborate (0.025 mol) and palladium acetate were sequentially added to 150 ml of DMF under nitrogen atmosphere. (0.0003mol),After stirring, a K3PO4 (0.045 mol) aqueous solution was added, and the mixture was refluxed at a temperature of 130 C for 10 h. After naturally cooling to room temperature, after completion of the reaction, 100 mL of deionized water was added, and a few drops of 2M HCl were added dropwise, extracted with dichloromethane, and the organic phase was collected and dried over anhydrous Na 2 SO 4 .deal with. The dried solution was filtered, and the solvent was removed on a rotary evaporator to give a crude material. The crude product was purified by silica gel column chromatography to afford intermediate M4 |
[ 1206249-65-1 ]
6-Bromo-4-chloropyridin-2-amine
Similarity: 0.73
[ 1206249-65-1 ]
6-Bromo-4-chloropyridin-2-amine
Similarity: 0.73
[ 1211521-46-8 ]
2-Bromo-4-chloro-3-methylpyridine
Similarity: 0.70
[ 1206249-65-1 ]
6-Bromo-4-chloropyridin-2-amine
Similarity: 0.73